Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Fmoc-L-HoSer(OTBMS)-OH is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1333332-17-4 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1333332-17-4 Structure
  • Basic information

    1. Product Name: Fmoc-L-HoSer(OTBMS)-OH
    2. Synonyms: Fmoc-L-HoSer(OTBMS)-OH;Fmoc-HomoSer(TBDMS)-OH≥ 97% (HPLC);(9H-Fluoren-9-yl)MethOxy]Carbonyl HomoSer(TBDMS)-OH;Fmoc-HoSer(TBDMS)-OH;O-(tert-Butyldimethylsilyl)-N-Fmoc-L-homoserine;Fmoc-hSerTBDMS-OH;Fmoc-L-HoSer(TBDMS)-OH;Fmoc-L-HomoSer(TMBDS)-OH
    3. CAS NO:1333332-17-4
    4. Molecular Formula: C25H33NO5Si
    5. Molecular Weight: 455.61872
    6. EINECS: N/A
    7. Product Categories: amino acid
    8. Mol File: 1333332-17-4.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 597.2±50.0 °C(Predicted)
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 1.137±0.06 g/cm3(Predicted)
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. PKA: 3.72±0.10(Predicted)
    10. CAS DataBase Reference: Fmoc-L-HoSer(OTBMS)-OH(CAS DataBase Reference)
    11. NIST Chemistry Reference: Fmoc-L-HoSer(OTBMS)-OH(1333332-17-4)
    12. EPA Substance Registry System: Fmoc-L-HoSer(OTBMS)-OH(1333332-17-4)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1333332-17-4(Hazardous Substances Data)

1333332-17-4 Usage

Chemical Properties

White to off-white powder

Check Digit Verification of cas no

The CAS Registry Mumber 1333332-17-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,3,3,3,3 and 2 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1333332-17:
(9*1)+(8*3)+(7*3)+(6*3)+(5*3)+(4*3)+(3*2)+(2*1)+(1*7)=114
114 % 10 = 4
So 1333332-17-4 is a valid CAS Registry Number.

1333332-17-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name Fmoc-Hse(TBDMS)-OH

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1333332-17-4 SDS

1333332-17-4Downstream Products

1333332-17-4Relevant articles and documents

α-Conotoxin ImI incorporating stable cystathionine bridges maintains full potency and identical three-dimensional structure

Dekan, Zoltan,Vetter, Irina,Daly, Norelle L.,Craik, David J.,Lewis, Richard J.,Alewood, Paul F.

, p. 15866 - 15869 (2011)

The two disulfide bonds of α-conotoxin ImI, a peptide antagonist of the α7 nicotinic acetylcholine receptor (nAChR), were systematically replaced with isosteric redox-stable cystathionine thioethers. Regioselective thioether formation was accomplished on solid support through substitution of a γ-chlorohomoalanine by an intramolecular cysteine thiol to produce hybrid thioether/disulfide analogues (2 and 3) as well as a dual cystathionine analogue (4) that were found to be structurally homologous to α-conotoxin ImI by 1H NMR. The antagonistic activity at the α7 nAChR of cystathionine analogue 3 (pIC50 = 6.41 ± 0.09) was identical to that of α-conotoxin ImI (1, pIC50 = 6.41 ± 0.09), whereas those of 2 (pIC50 = 5.96 ± 0.09) and 4 (pIC 50 = 5.89 ± 0.09) showed a modest decrease. The effect of oxidation of the thioethers to sulfoxides was also investigated, with significant changes in the biological activities observed ranging from a >30-fold reduction (2S=O) to a 3-fold increase (3S=OB) in potencies.

Noncovalent Protein Arginine Deiminase (PAD) Inhibitors Are Efficacious in Animal Models of Multiple Sclerosis

Tejeda, Elizabeth J. Curiel,Bello, Angelica M.,Wasilewski, Ewa,Koebel, Adam,Dunn, Shannon,Kotra, Lakshmi P.

, p. 8876 - 8887 (2017)

Peptidyl arginine deiminases have been shown to be hyperactive in neurodegenerative diseases including multiple sclerosis. An α-amino acid-based core structure, derived from a hydantoin core, with unique heterocycles on the side chains were synthesized as potential noncovalent inhibitors of PAD enzymes. Among the various heterocycles investigated, compound 23, carrying an imidazole moiety, exhibited the highest potency in this series with some selectivity for PAD2, and was further investigated in vivo. Pharmacokinetics in mice suggested the Cmax to be 12.0 ± 2.5 μg/mL and 170 ± 10 ng/mL in the serum and brain, respectively, when compound 23 was administered at 50 mg/kg via single dose ip. At the same dose, compound 23 also reversed physical disability and cleared the brain of T-cell infiltration in an EAE mouse model of multiple sclerosis (MS). This novel series of compounds show promise for further development as disease modifying agents for the potential treatment of MS.

A one-pot chemoenzymatic synthesis of (2S, 4R)-4-methylproline enables the first total synthesis of antiviral lipopeptide cavinafungin B

Zwick, Christian R.,Renata, Hans

, p. 6469 - 6473 (2018/10/05)

We report an efficient ten-step (longest linear sequence) synthesis of antiviral natural product cavinafungin B in 37% overall yield. By leveraging a one-pot chemoenzymatic synthesis of (2S,4R)-4-methylproline and oxazolidine-tethered (AT (Boc)G-Rink resin) SPPS methodology, the assembly of our molecular target could be conducted in an efficient manner. This general strategy could prove amenable to the construction of other natural and unnatural linear lipopeptides. The value of incorporating biocatalytic steps in complex molecule synthesis is highlighted by this work.

INHIBITORS OF PEPTIDYL ARGININE DEIMINASE (PAD) ENZYMES AND USES THEREOF

-

, (2017/03/14)

The present application relates to a-substituted amino acid compounds of the Formula (I), compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions characterized by or associated with the hypercitrullination of proteins by peptidyl arginine deiminase (PAD) enzymes.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1333332-17-4